Select Water Solutions announced a $700 million acquisition of Pilot Water Solutions, a private water midstream company with strong operations in the Delaware Basin. The deal includes $600 million in cash and $100 million in stock, plus $15 million in potential earnouts, and is expected to close in Q4 2026. This acquisition adds significant disposal and recycling capacity, long-term contracts, and projected EBITDA growth to Select's portfolio, strengthening its water infrastructure business to represent about 70% of pro forma profitability by 2027. The combined entity will benefit from operational synergies, enhanced contract visibility, and a strong balance sheet with net leverage below 2.0x at closing.
Select Water Solutions' acquisition announcement provides context for energy sector activity. For readers following the energy sector, here is Pluang's market snapshot as of Sep 25, 2026 02:31 WIB: Among 38 priced US energy stocks, 21 rose and 17 fell. Notable movers include Uranium Energy Corp (UEC) at USD 9.38 with a 1-day change of -5.68% and a typical hold time on Pluang of 35 days, Solaredge Technologies Inc (SEDG) at USD 32.00 with a 1-day change of -4.05%, and Cameco (CCJ) at USD 88.21 with a 1-day change of -2.85% and a typical hold time of 2 days.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
REGENXBIO announced positive 3-year results from its Phase II ALTITUDE trial of surabgene lomparvovec (sura-vec) for non-proliferative diabetic retinopathy (NPDR). A single in-office gene therapy dose led to over 60% of participants achieving more th...
Ethereum (ETH) has printed its first higher high since its August 2025 peak, breaking a year-long pattern of lower highs. It surpassed the $2,438 resistance level, which has now turned into support, signaling a more bullish weekly structure. However,...
